Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

2.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
3.

Detection of circulating tumor cells in different stages of prostate cancer.

Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, Heck MM, Andergassen U, Nawroth R, Gschwend JE, Retz M.

J Cancer Res Clin Oncol. 2013 May;139(5):755-63. doi: 10.1007/s00432-013-1377-5. Epub 2013 Jan 29.

PMID:
23358719
4.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

5.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ.

Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13.

PMID:
25595577
6.
7.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Amato RJ, Melnikova V, Zhang Y, Liu W, Saxena S, Shah PK, Jensen BT, Torres KE, Davis DW.

Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

PMID:
23622774
8.

Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.

Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C.

Urology. 2012 Dec;80(6):1328-32. doi: 10.1016/j.urology.2012.09.001. Epub 2012 Oct 10.

PMID:
23063057
9.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

10.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
11.

Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.

Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1457-64. doi: 10.1007/s00432-015-1936-z. Epub 2015 Feb 24.

PMID:
25708944
12.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

PMID:
21723797
13.

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.

14.

Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C.

J Clin Oncol. 2012 Feb 10;30(5):525-32. doi: 10.1200/JCO.2010.33.3716. Epub 2012 Jan 17.

PMID:
22253462
15.

The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.

Lowes LE, Lock M, Rodrigues G, D'Souza D, Bauman G, Ahmad B, Venkatesan V, Allan AL, Sexton T.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):358-64. doi: 10.1038/pcan.2015.36. Epub 2015 Aug 4.

16.

Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M.

Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16.

PMID:
26573830
17.

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.

Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2011 Sep;129(2):451-8. doi: 10.1007/s10549-011-1645-5. Epub 2011 Jun 28.

PMID:
21710134
18.

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS.

Ann Oncol. 2009 Jan;20(1):27-33. doi: 10.1093/annonc/mdn544. Epub 2008 Aug 11.

PMID:
18695026
19.

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.

Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA.

Gynecol Oncol. 2013 Nov;131(2):352-6. doi: 10.1016/j.ygyno.2013.08.006. Epub 2013 Aug 13.

PMID:
23954902
20.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G.

Lancet Oncol. 2009 Mar;10(3):233-9. doi: 10.1016/S1470-2045(08)70340-1. Epub 2009 Feb 11.

Supplemental Content

Support Center